Vanda Pharmaceuticals | VNDA - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.61B 225M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
J&J USD 17.24B 642M 2026-03
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD -566M 792M 2026-03
Novartis USD 10.82B 694M 2025-09
Pfizer USD 12.28B 8.74B 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Veracyte USD 101.97M 10.69M 2025-12